^
    3years
    A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL (clinicaltrials.gov)
    P1b, N=13, Completed, Memgen, LLC | Active, not recruiting --> Completed | Phase classification: P1 --> P1b
    Clinical • Trial completion • Phase classification • Combination therapy
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • ISF35